Protease inhibitors: a tale of two companies.
Cohen
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D018849:Controlled Clinical Trials as Topic; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry; D006678:HIV / Q000187:drug effects; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D019438:Ritonavir; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D013844:Thiazoles; D019469:Indinavir; D014633:Valine; D019438:Ritonavir